CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
pharmaphorum
NOVEMBER 2, 2022
The promise in the self-assembling RNA technology lies in its potential to achieve a strong immune response using a lower dose of antigen than the current generation of mRNA shots, although it is generally a larger molecule and may be more challenging to deliver.
52 
Let's personalize your content